Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | May 12, 2026 | May 14, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | SVP and CFO | March 01, 2022 | March 03, 2022 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Executive Vice President & CFO | July 22, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $533.92 · Expires 2036-05-11 | Direct | 525 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 525 · Balance 525 F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. |
| Deferred Stock UnitSEC Table II · derivative / convertible security | Direct | 1,354 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Grant · Acquired 234 · Balance 1,354 F2: Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.
F2: Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.
ILLUMINA, INC.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,297 |
Reported balance
After 2022-03-01 transaction · row 1
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 2,082 · Balance 11,297 F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2022, November 5, 2023, November 5, 2024, and November 5, 2025, subject to the awardee's continuing status as a service provider on such dates. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2024-12-29 | Direct | 6,246 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 6,246 · Balance 6,246 F2: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2022, November 5, 2023, November 5, 2024, and November 5, 2025, subject to the awardee's continuing status as a service provider on such dates.
F2: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates.
QUEST DIAGNOSTICS INC
Report date July 22, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,478 |
Reported balance
After 2026-07-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-22 · Grant · Acquired 102 · Balance 33,478 F1: Represents an award of restricted share units. F2: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted share units.
F2: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2026 Filed Jul 27, 2026 20:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 102 | $206.81 | $21,094.31 |
DisclosureSEC source: 0001022079-26-000081 · wk-form4_1785184405.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,478 F1 · security: Represents an award of restricted share units. F2 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 234 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000106 · wk-form4_1778792452.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,354 Underlying: Common Stock · 234 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 525 | $0.00 Strike: $533.92 | $0.00 |
DisclosureSEC source: 0000874716-26-000106 · wk-form4_1778792452.xml · derivative · entry 1 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525 Underlying: Common Stock · 525 shares Expires 2036-05-11 F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| April 20, 2026 Filed Apr 24, 2026 22:24 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 108 | $194.70 | $21,027.38 |
DisclosureSEC source: 0001022079-26-000050 · wk-form4_1777069487.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,376 F1 · security: Represents an award of restricted share units. F2 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:45 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 7,720 | $204.86 | $1,581,519.20 |
DisclosureSEC source: 0001022079-26-000032 · wk-form4_1772833514.xml · nonDerivative · entry 2 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,268 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:45 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 13,947 | $204.86 | $2,857,182.42 |
DisclosureSEC source: 0001022079-26-000032 · wk-form4_1772833514.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,988 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 869 | $204.86 | $178,023.34 |
DisclosureSEC source: 0001022079-26-000023 · wk-form4_1772660338.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,041 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:12 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 18,303 | $0.00 Strike: $204.96 | $0.00 |
DisclosureSEC source: 0001694295-26-000002 · wk-form4_1771625556.xml · derivative · entry 5 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,303 Underlying: Common Stock · 18,303 shares Expires 2036-02-18 F4 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:12 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,010 | $206.99 | $209,059.90 |
DisclosureSEC source: 0001694295-26-000002 · wk-form4_1771625556.xml · nonDerivative · entry 3 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,841 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:12 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 855 | $210.01 | $179,558.55 |
DisclosureSEC source: 0001694295-26-000002 · wk-form4_1771625556.xml · nonDerivative · entry 2 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,851 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:12 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 3,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001694295-26-000002 · wk-form4_1771625556.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,706 F1 · security: Represents an award of restricted stock units. Read SEC document |
| January 28, 2026 Filed Feb 20, 2026 22:12 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 69 | $183.51 | $12,662.47 |
DisclosureSEC source: 0001694295-26-000002 · wk-form4_1771625556.xml · nonDerivative · entry 4 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,910 F3 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| October 21, 2025 Filed Oct 24, 2025 22:11 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 68 | $189.08 | $12,857.51 |
DisclosureSEC source: 0001022079-25-000231 · wk-form4_1761343900.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,741 F1 · security: Represents an award of restricted share units. F2 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| July 21, 2025 Filed Jul 25, 2025 20:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | OtherCommon Stock | 72 | $167.50 | $12,059.71 |
DisclosureSEC source: 0001022079-25-000189 · wk-form4_1753475333.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,673 F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| July 16, 2025 Filed Jul 17, 2025 20:26 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 850 | $169.01 | $143,658.50 |
DisclosureSEC source: 0001022079-25-000168 · wk-form4_1752783979.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,601 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted stock units. Read SEC document |
| May 07, 2025 Filed May 8, 2025 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000081 · wk-form4_1746745281.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257 Underlying: Common Stock · 257 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. Read SEC document |
| May 07, 2025 Filed May 8, 2025 23:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 600 | $0.00 Strike: $486.61 | $0.00 |
DisclosureSEC source: 0000874716-25-000081 · wk-form4_1746745281.xml · derivative · entry 1 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires 2035-05-06 F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| April 21, 2025 Filed May 2, 2025 20:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | OtherCommon Stock | 74 | $164.42 | $12,167.23 |
DisclosureSEC source: 0001022079-25-000130 · wk-form4_1746217999.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,451 F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 7,684 | $173.74 | $1,335,018.16 |
DisclosureSEC source: 0001022079-25-000085 · wk-form4_1741210425.xml · nonDerivative · entry 2 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,377 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 13,884 | $173.74 | $2,412,206.16 |
DisclosureSEC source: 0001022079-25-000085 · wk-form4_1741210425.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,061 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:40 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 869 | $171.75 | $149,250.75 |
DisclosureSEC source: 0001022079-25-000076 · wk-form4_1740778812.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,177 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:45 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 1,031 | $169.71 | $174,971.01 |
DisclosureSEC source: 0001022079-25-000060 · wk-form4_1740174343.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,046 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 17,403 | $0.00 Strike: $165.30 | $0.00 |
DisclosureSEC source: 0001022079-25-000037 · wk-form4_1739572188.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,403 Underlying: Common Stock · 17,403 shares Expires 2035-02-12 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 4,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-25-000037 · wk-form4_1739572188.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,077 F1 · security: Represents an award of restricted stock units. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:30 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | OtherCommon Stock | 35 | $158.04 | $5,531.26 |
DisclosureSEC source: 0001022079-25-000017 · wk-form4_1738359038.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,539 F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| October 21, 2024 Filed Oct 25, 2024 20:26 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | OtherCommon Stock | 37 | $149.37 | $5,526.73 |
DisclosureSEC source: 0001022079-24-000198 · wk-form4_1729887986.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,504 F1 · security: Represents an award of restricted share units. F2 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| July 22, 2024 Filed Jul 26, 2024 22:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | OtherCommon Stock | 21 | $146.97 | $3,086.45 |
DisclosureSEC source: 0001022079-24-000167 · wk-form4_1722033170.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,467 F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 20:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 3,910 | $142.65 | $557,761.50 |
DisclosureSEC source: 0001022079-24-000145 · wk-form4_1721334700.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,446 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000103 · wk-form4_1715209335.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 863 Underlying: Common Stock · 262 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 609 | $0.00 Strike: $476.87 | $0.00 |
DisclosureSEC source: 0000874716-24-000103 · wk-form4_1715209335.xml · derivative · entry 1 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609 Underlying: Common Stock · 609 shares Expires 2034-05-05 F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| April 22, 2024 Filed Apr 26, 2024 21:43 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 24 | $126.25 | $3,029.88 |
DisclosureSEC source: 0001022079-24-000104 · wk-form4_1714167806.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,356 F1 · security: Represents an award of restricted share units. F2 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:46 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 656 | $126.36 | $82,892.16 |
DisclosureSEC source: 0001022079-24-000081 · wk-form4_1709329574.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,332 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:03 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 22,835 | $0.00 Strike: $127.81 | $0.00 |
DisclosureSEC source: 0001022079-24-000032 · wk-form4_1708131808.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,835 Underlying: Common Stock · 22,835 shares Expires 2034-02-14 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:03 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 5,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-24-000032 · wk-form4_1708131808.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,988 F1 · security: Represents an award of restricted share units. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:38 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 17 | $129.33 | $2,198.56 |
DisclosureSEC source: 0001022079-24-000015 · wk-form4_1706909908.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| October 23, 2023 Filed Oct 26, 2023 22:15 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 18 | $122.86 | $2,211.55 |
DisclosureSEC source: 0001022079-23-000162 · wk-form4_1698358531.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,493 F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 20:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 3,909 | $140.18 | $547,963.62 |
DisclosureSEC source: 0001022079-23-000126 · wk-form4_1689626237.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,475 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 257 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000874716-23-000081 · wf-form4_168453019248270.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 601 Underlying: Common Stock · 257 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F2 · price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F2 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F2 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 645 | $0.00 Strike: $487.12 | $0.00 |
DisclosureSEC source: 0000874716-23-000081 · wf-form4_168453019248270.xml · derivative · entry 1 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645 Underlying: Common Stock · 645 shares Expires 2033-05-16 F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:50 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 18,616 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000036 · wf-form4_167753460967466.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,616 Underlying: Common Stock · 18,616 shares Expires 2033-02-23 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:50 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 4,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000036 · wf-form4_167753460967466.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,384 F1 · security: Represents an award of restricted share units. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:10 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 945 | Not disclosed Strike: $333.90 | Not disclosed |
DisclosureSEC source: 0001567619-22-010582 · doc1.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945 Underlying: Common Stock · 945 shares Expires 2032-05-10 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:10 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-010582 · doc1.xml · derivative · entry 1 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344 Underlying: Common Stock · 344 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F3 · price: Not applicable. F1 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. F1 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:43 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 6,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008120 · form4.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,246 Underlying: Common Stock · 6,246 shares Expires 2024-12-29 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:43 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 2,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008120 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,297 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2022, November 5, 2023, November 5, 2024, and November 5, 2025, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:39 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 4,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006629 · form4.xml · derivative · entry 3 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,561 shares Expires 2022-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2018. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2018. F1 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2018. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:39 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,808 | $319.86 | $578,306.88 |
DisclosureSEC source: 0001127602-22-006629 · form4.xml · nonDerivative · entry 2 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,215 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:39 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 4,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006629 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2018. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:07 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 723 | $408.14 | $295,085.22 |
DisclosureSEC source: 0001127602-21-028727 · form4.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,462 Read SEC document |
| May 12, 2021 Filed May 14, 2021 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 723 | Not disclosed Strike: $512.31 | Not disclosed |
DisclosureSEC source: 0001567619-21-010256 · doc1.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723 Underlying: Common Stock · 723 shares Expires 2031-05-11 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.